Evidence for MHC I–restricted CD8+ T-cell–mediated immunopathology in canine masticatory muscle myositis and polymyositis

Novel Management of Masticatory Myositis in Three Dogs with a Selective Janus Kinase (JAK-1) Inhibitor

Masticatory myositis (MM) is an inflammatory myopathy reported in dogs and is characterized by inflammation of the masticatory muscles (temporalis, masseter, and pterygoid muscles). Immunosuppressive therapy is the current recommended treatment for MM and may involve glucocorticoids, cyclosporine, azathioprine, mycophenolate mofetil, leflunomide, or a combination of these treatments that are slowly tapered to the lowest effective dose. However, side effects from multimodal medical therapy and complications associated with MM relapses have been reported. The purpose of this case series was to report oclacitinib as a treatment alternative to traditional medical management of MM. The intent of this alternative is to manage side effects from glucocorticoid use. Oclacitinib (1mg/kg per os q12h) was used solely for treatment of MM in three dogs. The dogs were followed up to >6 months after oclacitinib administration. An increase in oral range of motion, as determined by gape angle, was noted in all three dogs. However, a corresponding drop in antibody titers (2M fiber) did not occur. All dogs showed improvement in overall clinical management of MM, side effects from glucocorticoids, and clinical signs related to chronic prednisone use. Larger controlled trials with consistent measurements (interincisal distance, gape angle) and 2M fiber antibody titers are indicated to further assess validation of oclacitinib treatment of MM. The clinical outcome of all dogs was considered successful.

Electrophysiological and clinical examination of polymyositis: a retrospective analysis

BACKGROUND

We retrospectively analyzed electromyogram (EMG), laboratory and clinical data of 93 patients with polymyositis (PM) to help improve early diagnostic accuracy.

METHODS

Data were collected from hospitalized patients who were diagnosed with PM between January 1, 2006 and April 1, 2010 at Chinese People's Liberation Army General Hospital.

RESULTS

Eighty-six (92.47%) patients exhibited an isolated myopathic EMG pattern, 3 (3.23%) showed myopathy combined with neuropathy and 1 (1.08%) had diabetes mellitus. Among the 4 without myopathic EMG, 1 had inflammatory myopathy, and 3 had prior corticosteroid treatment with clinical improvement before EMG examination. Muscle biopsy, performed in 40 cases, inclusive of the 7 cases that did not show an isolated myopathic EMG patterns, revealed that 80% exhibited typical pathological features of PM, 17.5% showed nonspecific muscle fiber necrosis and 2.5% were normal. EMG showed that tibialis anterior and biceps brachii exhibited more abnormal EMG results than abductor pollicis brevis. Patients with disease duration >3 months had significantly higher alanine aminotransferase and reduced motor unit potential (MUP) amplitudes compared to patients with shorter disease duration. Statistical analysis revealed a significant association between disease duration and MUP amplitude reduction. Patients without interstitial lung disease showed significantly longer disease duration and higher creatine kinase and lactate dehydrogenase levels than patients with interstitial lung disease.

CONCLUSIONS

Our results show that MUP is a sensitive yardstick for diagnosis of PM and is inversely related to disease duration. Our study also highlights that selecting specific muscles for EMG may improve diagnostic accuracy in PM.

Use of MRI for the Early Diagnosis of Masticatory Muscle Myositis

The medical records of two dogs that were diagnosed with masticatory muscle myositis (MMM) were reviewed. The reported clinical signs included intense pain when opening the mouth and restricted jaw movement. MRI detected widespread, symmetrical, and inhomogeneously hyperintense areas in the masticatory muscle. Electromyography (EMG) demonstrated severe and spontaneous pathologic activity in the temporal and masseter muscles. With early therapeutic treatment, remission of symptoms occurred within 2 mo, and no relapses were observed for the subsequent 2 yr. The gold standard for the diagnosis of MMM is the 2M antibody test, but the purpose of this study was to evaluate the use of MRI as an accurate and efficient diagnostic tool for the initiation of early therapy for the treatment of muscle myositis.

Polymyositis following Vogt-Koyanagi-Harada-like syndrome in a Jack Russell terrier

A male Jack Russell terrier developed bilateral uveitis and glaucoma at 1 year of age. Since the ocular disease was painful and unresponsive to treatment, both globes were enucleated. Microscopical evaluation of one enucleated globe revealed panuveitis, with pigment dispersion and phagocytosis consistent with the ocular lesions of canine Vogt-Koyanagi-Harada (VKH)-like syndrome. Three years later the dog was represented with severe muscle disease and skin lesions. Due to rapid clinical deterioration the dog was humanely destroyed. Necropsy examination revealed lichenoid interface inflammation in the skin and mucous membranes, with pigmentary incontinence consistent with VKH-like syndrome and lymphocytic and histiocytic polymyositis with marked muscle atrophy. Canine VKH-like syndrome is an autoimmune disease that targets melanocyte antigens. Some human patients with VKH disease develop additional autoimmune diseases. To our knowledge this is the first reported case of polymyositis subsequent to VKH-like disease in a dog. In addition, VKH-like disease has not been previously reported in a Jack Russell terrier.

Orbital inflammatory disease and pseudotumor in dogs and cats

Orbital disease is common in dogs and cats. Clinical signs include exophthalmos, protrusion of the third eyelid, and resistance to retropulsion of the globe. This article discusses diagnostic work-up for dogs and cats with signs suggestive of orbital disease. Diagnosis and treatment of nonneoplastic orbital diseases follows. Congenital diseases are discussed first, followed by inflammatory diseases of the orbit including orbital pseudotumor. Lastly, other less common orbital conditions are addressed.

Computed tomographic appearance of masticatory myositis in dogs: 7 cases (1999–2006)

OBJECTIVE

To document computed tomography (CT) features in dogs with masticatory myositis.

DESIGN

Retrospective case series.

ANIMALS

7 dogs with an immunologic diagnosis of masticatory myositis and an absence of clinical abnormalities of any skeletal muscles other than the masticatory muscles.

PROCEDURES

History; clinical, hematologic, biochemical, immunologic, cytologic, and histologic findings; and pre- and postcontrast CT imaging features of masticatory muscles and head and neck lymph nodes were extracted from medical records.

RESULTS

On CT images, changes in size (atrophy or swelling) were common for all masticatory muscles except the digastricus muscles, which were involved only in 1 dog. Pre-contrast attenuation changes, most often hypoattenuation with varied distribution patterns, were seen in masticatory muscles of 4 dogs. Contrast enhancement with a predominantly inhomogeneous distribution pattern was seen in the temporalis, masseter, and pterygoid muscles of all dogs. Head and neck lymph nodes were enlarged in all but 1 dog and had contrast enhancement with predominantly central or homogeneous distribution patterns. Muscle biopsy was performed in 6 dogs, with biopsy specimens obtained from areas that had the most obvious contrast enhancement on CT images. For all 6 dogs, biopsy specimens had histologic features indicative of masticatory myositis.

CONCLUSIONS AND CLINICAL RELEVANCE

Results suggested that CT may be a useful adjunct in the diagnosis of masticatory myositis in dogs, including selection of sites for diagnostic muscle biopsy.